Payment overview · 2025
General Payments
$14.97
1 reported records · 1 companies
Healthcare provider profile · identity verified
Jeffrey Wells, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SCHNECKSVILLE, PA · NPI 1669767992
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Wells, D.O. received $14.97 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.97 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $14.97 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 426 | 108 |
| Simvastatin | Simvastatin | 381 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 88 |
| Omeprazole | Omeprazole | 312 | 77 |
| Losartan Potassium | Losartan Potassium | 306 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 288 | 74 |
| Lisinopril | Lisinopril | 270 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 224 | 59 |
| Metformin Hcl Er | Metformin Hcl | 219 | 58 |
| Furosemide | Furosemide | 184 | 48 |
| Famotidine | Famotidine | 178 | 49 |
| Eliquis | Apixaban | 174 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 41 |
| Gabapentin | Gabapentin | 143 | 35 |
| Glimepiride | Glimepiride | 133 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 31 |
| Tramadol Hcl | Tramadol Hcl | 125 | 28 |
| Alprazolam | Alprazolam | 121 | 44 |
| Prednisone | Prednisone | 120 | 61 |
| Allopurinol | Allopurinol | 119 | 28 |
| Atenolol | Atenolol | 115 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 30 |
| Januvia | Sitagliptin Phosphate | 106 | 21 |
| Ozempic | Semaglutide | 101 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 91 | 17 |
| Sertraline Hcl | Sertraline Hcl | 88 | 22 |
| Metformin Hcl | Metformin Hcl | 87 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 19 |
| Montelukast Sodium | Montelukast Sodium | 75 | 22 |
| Potassium Chloride | Potassium Chloride | 73 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 70 | 39 |
| Carvedilol | Carvedilol | 69 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 17 |
| Lorazepam | Lorazepam | 67 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 16 |
| Cephalexin | Cephalexin | 59 | 46 |
| Methocarbamol | Methocarbamol | 59 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 14 |
| Meloxicam | Meloxicam | 57 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 15 |
| Warfarin Sodium | Warfarin Sodium | 52 | 13 |
| Trazodone Hcl | Trazodone Hcl | 51 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 12 |
| Valsartan | Valsartan | 49 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 46 | 37 |
| Synthroid | Levothyroxine Sodium | 46 | 11 |
| Tradjenta | Linagliptin | 46 | suppressed |
| Finasteride | Finasteride | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 15 |
| Ezetimibe | Ezetimibe | 43 | 12 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 31 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 19 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 30 | 27 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Jantoven | Warfarin Sodium | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Trimethoprim | Trimethoprim | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Zocor | Simvastatin | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14.97 · 1 records | Novo Nordisk Inc | Wegovy | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error